34,013 Shares in CeriBell (NASDAQ:CBLL) Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. bought a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 34,013 shares of the company's stock, valued at approximately $880,000. JPMorgan Chase & Co. owned 0.09% of CeriBell at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rhumbline Advisers bought a new stake in shares of CeriBell in the fourth quarter valued at $320,000. Corebridge Financial Inc. bought a new stake in CeriBell in the 4th quarter valued at about $158,000. PNC Financial Services Group Inc. purchased a new stake in CeriBell during the fourth quarter valued at about $47,000. Vanguard Group Inc. bought a new position in CeriBell during the fourth quarter worth about $18,015,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of CeriBell in the fourth quarter worth about $628,000.

Wall Street Analyst Weigh In

Several research analysts recently commented on CBLL shares. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $32.50.

CeriBell Trading Up 0.2 %

Shares of CBLL stock traded up $0.04 during trading hours on Friday, reaching $16.32. The stock had a trading volume of 208,040 shares, compared to its average volume of 270,817. The stock has a fifty day simple moving average of $18.85. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million. Sell-side analysts predict that CeriBell will post -2.46 EPS for the current year.

Insider Buying and Selling

In other news, CEO Xingjuan Chao sold 15,628 shares of CeriBell stock in a transaction dated Wednesday, April 23rd. The stock was sold at an average price of $15.11, for a total transaction of $236,139.08. Following the completion of the sale, the chief executive officer now owns 727,151 shares in the company, valued at approximately $10,987,251.61. This trade represents a 2.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 24,700 shares of company stock worth $372,434 over the last ninety days.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.